
primary studies - published RCT

Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study.

Code: PM41138737

Year: 2026 **Date:** 1989

Author: Sermet-Gaudelus I

Study design (if review, criteria of inclusion for studies)

randomised crossover trial

Interventions

The number of capsules of Cotazym-S-Forte (10,000 BP units of lipase activity per capsule) administered was half the usual number of Pancrease capsules (5000 BP units lipase per capsule)

Outcome measures

fat absorption

Main results

Cotazym-S-Fortewas associated with the same degree of fat absorption as Pancrease.

[http://dx.doi.org/10.1016/S2213-2600\(25\)00248-6](http://dx.doi.org/10.1016/S2213-2600(25)00248-6)

See also

Lancet Respir Med. 2026 Jan;14(1):38-48. doi: 10.1016/S2213-2600(25)00248-6. Epub 2025 Oct 22.

Keywords

Adolescent; Child; Delayed-Action Preparations; Drug Administration Schedule; Infant; pharmacological_intervention; Pancreatic Enzyme Replacement Therapy; Supplementation; Pancreas insufficiency; Pancreatic Diseases; Gastrointestinal Diseases; Malabsorption; Nutrition Disorders; Capsules; Gastrointestinal Agents;